Literature DB >> 8244121

Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.

C J Hawkey1, R G Long, K D Bardhan, K G Wormsley, K M Cochran, J Christian, I K Moules.   

Abstract

The purpose of this study was to compare duodenal ulcer healing, symptom relief, and safety of lansoprazole (a new proton pump inhibitor) given at doses of 30 mg and 60 mg, in the morning with ranitidine 300 mg at bedtime. Two hundred and eighty nine patients were enrolled over a 20 month period in a double blind randomised parallel group comparative study set in outpatient endoscopy units of six United Kingdom medical centres. Patients were randomised to receive lansoprazole 30 mg in the morning (n = 95), 60 mg in the morning (n = 96), or ranitidine 300 mg at bedtime (n = 98) for four weeks. Efficacy was assessed by gastroscopy at study entry and after two and four weeks of treatment. Symptom relief was monitored by patient diaries and physician review at two and four weeks. Both doses of lansoprazole resulted in significantly greater ulcer healing than ranitidine after two and four weeks. Respective healing rates on lansoprazole 30 mg, 60 mg, and ranitidine 300 mg were 78%, 80%, and 60% after two weeks and 93%, 97%, and 81% after four weeks. Patients on lansoprazole 30 mg (p = 0.002) and lansoprazole 60 mg (p = 0.026) also recorded greater relief of night time pain in the diary cards during the first seven days of treatment than those on ranitidine. Patients on lansoprazole 60 mg reported significantly better pain relief at their two week visit compared with those receiving ranitidine (p = 0.007). There were no differences between treatment groups in the occurrence or pattern of adverse drug reactions during the trial. It is concluded that for patients with duodenal ulcer, lansoprazole 30 mg or 60 mg is associated with faster ulcer healing and better symptom relief than ranitidine 300 mg at bedtime. There were no significant differences between lansoprazole 30 mg and 60 mg. These data indicate that lansoprazole should be used at a once daily dose of 30 mg for the treatment of duodenal ulcer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8244121      PMCID: PMC1374562          DOI: 10.1136/gut.34.10.1458

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  Human gastric acid secretion following repeated doses of AG-1749.

Authors:  P Müller; H G Dammann; U Leucht; B Simon
Journal:  Aliment Pharmacol Ther       Date:  1989-04       Impact factor: 8.171

2.  Explanatory and pragmatic attitudes in therapeutical trials.

Authors:  D Schwartz; J Lellouch
Journal:  J Chronic Dis       Date:  1967-08

3.  Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.

Authors:  H Nagaya; H Satoh; K Kubo; Y Maki
Journal:  J Pharmacol Exp Ther       Date:  1989-02       Impact factor: 4.030

4.  Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.

Authors:  H Satoh; N Inatomi; H Nagaya; I Inada; A Nohara; N Nakamura; Y Maki
Journal:  J Pharmacol Exp Ther       Date:  1989-02       Impact factor: 4.030

5.  Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells.

Authors:  H Nagaya; H Satoh; Y Maki
Journal:  J Pharmacol Exp Ther       Date:  1990-03       Impact factor: 4.030

6.  Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration.

Authors:  J Hotz; R Kleinert; T Grymbowski; U Hennig; J A Schwarz
Journal:  Aliment Pharmacol Ther       Date:  1992-02       Impact factor: 8.171

Review 7.  Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.

Authors:  L B Barradell; D Faulds; D McTavish
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

8.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.

Authors:  E Fellenius; T Berglindh; G Sachs; L Olbe; B Elander; S E Sjöstrand; B Wallmark
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

9.  Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole.

Authors:  W Londong; H Barth; H G Dammann; K J Hengels; R Kleinert; P Müller; H Rohde; B Simon
Journal:  Aliment Pharmacol Ther       Date:  1991-06       Impact factor: 8.171

  9 in total
  9 in total

1.  Therapeutic effects of mosapride citrate and lansoprazole for prevention of aspiration pneumonia in patients receiving gastrostomy feeding.

Authors:  Kento Takatori; Rihito Yoshida; Aya Horai; Shinya Satake; Takayuki Ose; Naoto Kitajima; Shushi Yoneda; Kyoichi Adachi; Yuji Amano; Yoshikazu Kinoshita
Journal:  J Gastroenterol       Date:  2012-12-13       Impact factor: 7.527

Review 2.  pH, healing rate and symptom relief in acid-related diseases.

Authors:  J Q Huang; R H Hunt
Journal:  Yale J Biol Med       Date:  1996 Mar-Apr

3.  Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration.

Authors:  R J Brummer; B J Geerling; R W Stockbrügger
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

Review 4.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of lansoprazole.

Authors:  B D Landes; J P Petite; B Flouvat
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

Review 6.  Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

Review 7.  Acid, protons and Helicobacter pylori.

Authors:  G Sachs; K Meyer-Rosberg; D R Scott; K Melchers
Journal:  Yale J Biol Med       Date:  1996 May-Jun

8.  Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.

Authors:  D C Metz; J R Pisegna; G L Ringham; K Feigenbaum; P D Koviack; P N Maton; J D Gardner; R T Jensen
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199

9.  Mucosal Healing Effectiveness and Safety of Anaprazole, a Novel PPI, vs. Rabeprazole in Patients With Duodenal Ulcers: A Randomized Double-Blinded Multicenter Phase II Clinical Trial.

Authors:  Xu Shu; Zhenhua Zhu; Yu Fu; Zhenyu Zhang; Jiangbin Wang; Xing Li; Shuixiang He; Huizhen Fan; Side Liu; Guoxin Zhang; Jianhua Tang; Caibin Huang; Qin Du; Xiaoyan Wang; Baohong Xu; Yiqi Du; Qikui Chen; Bangmao Wang; Ying Chen; Xianghui Duan; Yong Xie; Lijuan Huo; Xiaohua Hou; Nonghua Lu
Journal:  Front Med (Lausanne)       Date:  2021-07-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.